Prophylactic use of anti-emetic medications for gastrointestinal adverse events caused by iraglutide in patients with type 2 diabetes

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1900026184

Enrollment

Unknown

Registered

2019-09-25

Start date

2019-10-01

Completion date

Unknown

Last updated

2019-09-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes

Interventions

Vacuity contrast group:Placebo

Drug control group:Metoclopramide

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Type 2 diabetes patients; (2) older than 18 years and younger than 65 years of age; (3) non-pregnant, non-lactating; (4) BMI 25–35 kg /m2; (5) glycated hemoglobin between 7.1–11.0%.

Exclusion criteria

Exclusion criteria: Use of weight-loss drugs, corticosteroids, drugs known to affect gastrointestinal motility, or any investigational drug; Any previous exposure to exenatide or a GLP-1 analogue.

Design outcomes

Primary

Measure	Time frame
Shedding Rate;Glycated hemoglobin;	—

Secondary

Measure	Time frame
nausea;Vomiting;diarrhea;stomach ache;constipation;Bloating;body weight;Blood lipid;	—

Countries

China

Contacts

Public ContactJin Zheng

Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine

kingz1025@163.com+86 13675853969

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026